Patients with nasopharyngeal carcinoma often exhibit clinical manifestations of excessive sputum, which is considered to be symptomatic of middle to late stages of nasopharyngeal carcinoma. For patients with middle to late stages of nasopharyngeal carcinoma, their immunity is compromised, and this decrease in immunity becomes more pronounced after receiving anti-tumor treatments such as radiotherapy and chemotherapy. As a result, patients are highly susceptible to concurrent infections, primarily manifesting symptoms related to the respiratory system such as coughing, sputum production, fever, and chest pain. Additionally, late-stage nasopharyngeal carcinoma patients may also experience metastasis to the lungs. When lung metastasis occurs, patients may develop obstructive pneumonia, which can also lead to the clinical presentation of excessive sputum. Moreover, some patients may exhibit increased sputum production as a side effect of anti-tumor treatments.